Learn what’s fueling San Francisco’s boom in AI, big data, and R&D, explore promising investment and partnership opportunities, and align the latest trends and technologies with your business by listening to our podcast and downloading our special report complem...
The quantity of data about medicines, diseases, and biology is growing. So too, are the number of companies that employ artificial intelligence in drug discovery. Most of the low-hanging fruit in drug research has already been picked, and the industry is clamoring to ma...
A growing population of people with software experience plus an interest in life sciences is boosting drug development in the San Francisco Bay Area, according to panelists at an Xcelerating event. Innovation in the San Francisco Bay Area may first bring to mind tech be...
Join Xconomy online this Thursday, June 25 for Xcelerating Life Sciences San Francisco: The AI, Big Data, and R&D Boom forum and networking event to explore the latest technology and business trends in AI and drug development through the lens of some of the Bay Area...
The early bird sale for Xcelerating Life Sciences San Francisco: The AI, Big Data, and R&D Boom ends this Friday at 11:59 p.m. PT. Register today to lock in the low $99 rate and secure your spot at the online forum and networking event on June 25. This is your chanc...
A stem cell biologist, a gene editing expert, and a data engineer walk into a room…and that’s just a few of the people Daphne Koller has recruited in the past two years to Insitro. The South San Francisco-based startup has grand plans to reevaluate and, potentia...
Speeding up and bringing down the cost of clinical trials would be a huge boon to pharma companies and patients alike. San Francisco-based startup Unlearn.AI says it has developed proprietary technology that may help accomplish just that. On Monday the company announced...
Two venture-backed startups that have developed technologies intended to speed up the drug discovery and development process are combining those tools in a bid to achieve their goals together. San Francisco-based Atomwise has developed deep learning techniques for use i...
In startup world these days, the word “biotech” is increasingly accompanied by “computational” and two, two-letter initialisms: AI and ML. Those tools—artificial intelligence and machine learning, respectively—have been around for decades, but in rec...
Rare disease drug developer BridgeBio is now a public company, raising $348.5 million in the biggest biotech IPO so far this year. On Wednesday night, BridgeBio priced its stock offering of 20.5 million shares at $17 each, topping the $14 to $16 per share price range it...